FDA accepts Foamix NDA for acne treatment FMX101; shares up 4% premarket

|About: Foamix Pharmaceuticals... (FOMX)|By:, SA News Editor

Foamix Pharmaceuticals (NASDAQ:FOMX) is up 4% premarket on modest volume following the FDA's acceptance of its marketing application seeking approval for FMX101, a topical minocyline foam, for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients at least nine years old.

The agency's action date is October 20.

Subscribe for full text news in your inbox